As Executive Chairman of the Board of Antylia Scientific, Bernd leads with a persistent drive toward customer-driven organic and inorganic innovation leading to sustainable and profitable growth.

Bernd served as Chairman and CEO of Antylia Scientific from 2014 through December 2021. Before joining Antylia Scientific, Bernd served as President and CEO of Qualicaps, a provider of capsule manufacturing and processing equipment for pharmaceutical companies, which sold to Mitsubishi Chemical Holdings in 2013.

Prior to Qualicaps, he was Chief Commercial Operations Officer at Life Technologies Corporation, where he was responsible for its $3.5 billion global business. Bernd held prior leadership roles with Invitrogen Corporation (a predecessor of Life Technologies) and with GE Medical Systems.

As CEO of Antylia Scientific, Jon is focused on expanding our product portfolio to include more innovative scientific tools enabling our customers to discover and manufacture new therapeutics, vaccines & diagnostics. Beyond his company-wide leadership responsibilities, Jon oversees strategic planning initiatives for Antylia Scientific (including mergers and acquisitions).

Prior to joining Antylia Scientific in November 2015, Jon co-founded and served as the Executive Vice President of Devicor Medical Products, a GTCR-portfolio company sold to the Danaher Corporation in November 2014. Prior to Devicor, Jon was a Managing Director in the Healthcare group at the Royal Bank of Scotland plc.

Earlier in his career, Jon had numerous roles in Corporate Development and M&A with Cardinal Health, Dresdner Kleinwort Wasserstein (formerly Wasserstein Perella) and Deutsche Bank (formerly BT Wolfensohn).

Leading Human Resources and Integrations for Antylia Scientific, Mina’s responsibilities span Human Resources, integrations and communications.

Prior to joining Antylia Scientific, Mina was with Life Technologies. There she played a range of leadership roles including Talent Management and Human Resources for the Commercial and the Genetic Sequencing businesses, which combined to provide a valuable view into the importance of organizational and people strategies in the development of biotechnology capabilities.

Earlier in her career, Mina held leadership positions in Human Resources in diverse industries represented by GSK, Electronic Arts and The Coca-Cola Company.